Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

Similar articles for PubMed (Select 21973297)

1.

Early viral kinetics: a novel guide for optimal dosing frequency of pegylated interferon-α-2a in HIV/HCV-coinfected patients.

Milazzo L, Cesari M.

Expert Rev Anti Infect Ther. 2011 Oct;9(10):859-62. doi: 10.1586/eri.11.100.

PMID:
21973297
2.

Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.

Tural C, Solà R, Alvarez NP, Moltó J, Sánchez M, Zamora AM, Ornelas A, Laguno M, González J, von Wichmann MÁ, Téllez MJ, Paredes R, Clotet B; CORAL-2 study group.

Antivir Ther. 2011;16(6):833-41. doi: 10.3851/IMP1837.

PMID:
21900715
3.

Pegylated interferons for the treatment of chronic hepatitis C infection.

Luxon BA, Grace M, Brassard D, Bordens R.

Clin Ther. 2002 Sep;24(9):1363-83. Review.

PMID:
12380630
4.

Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.

Tural C, Galeras JA, Planas R, Coll S, Sirera G, Giménez D, Salas A, Rey-Joly C, Cirera I, Márquez C, Tor J, Videla S, García-Retortillo M, Clotet B, Solà R.

Antivir Ther. 2008;13(8):1047-55.

PMID:
19195330
5.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
7.

Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.

Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Loncá M, Martinez E, Sánchez-Tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):174-8.

PMID:
17106276
8.
9.

Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients.

Ballesteros AL, Fuster D, Planas R, Clotet B, Tural C.

J Antimicrob Chemother. 2005 Jun;55(6):824-7. Epub 2005 May 10.

11.
12.

Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.

Lopez-Cortes LF, Valera-Bestard B, Gutierrez-Valencia A, Ruiz-Valderas R, Jimenez L, Arizcorreta A, Terrón A, Viciana P.

Clin Pharmacol Ther. 2008 Nov;84(5):573-80. doi: 10.1038/clpt.2008.110. Epub 2008 Jul 2.

PMID:
18596682
13.

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH.

Clin Infect Dis. 2008 Nov 15;47(10):1260-9. doi: 10.1086/592579.

14.

Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.

Núñez M, Mariño A, Miralles C, Berdún MA, Sola J, Hernandez-Burruezo JJ, Galindo MJ, Barreiro P, Martin-Carbonero L, Soriano V.

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):439-44. Erratum in: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):528. Mariño, Angel [corrected to Mariño, Ana].

PMID:
17468669
15.

Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.

Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G.

Antivir Ther. 2004 Aug;9(4):491-7.

PMID:
15456079
16.

Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.

Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, Rodríguez-Frias F, Falco V, Curran A, Imaz A, Villar del Saz S, Ocaña I, Esteban R, Pahissa A.

Clin Infect Dis. 2009 Apr 15;48(8):1152-9. doi: 10.1086/597470. Erratum in: Clin Infect Dis. 2009 Aug 1;49(3):489.

17.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
18.

Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW.

Gastroenterology. 2002 Oct;123(4):1070-83.

PMID:
12360469
19.

Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort.

Vogel M, Dominguez S, Bhagani S, Azwa A, Page E, Guiguet M, Valantin MA, Katlama C, Rockstroh JK, Nelson M.

Antivir Ther. 2010;15(2):267-79. doi: 10.3851/IMP1501.

PMID:
20386082
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk